Dr. Lisa Plitnick is a Senior Principal Investigator, Vaccines Therapeutic Area Lead, in the Department of Safety Assessment and Laboratory Animal Resources in Merck Research Laboratories, Merck & Co., Inc. Lisa joined MRL in 2002 and currently serves as the Therapeutic Area Lead for Vaccines and a Nonclinical Safety Lead on drug development teams. Lisa is also the Scientific and Regulatory Advisor for the in Vivo Biologics Release Testing Group in the Merck Manufacturing Division. Her Therapeutic Area Lead responsibilities include oversight of more than 20 programs including traditional and novel vaccine platforms from early nonclinical development through marketing. As a Nonclinical Safety Lead, Lisa has been responsible for small molecule, biologic and vaccine programs in various therapeutic areas including infectious diseases, atherosclerosis, diabetes, asthma, osteoporosis and obesity. Lisa is co-editor of a book entitled Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics and has written and/or contributed to several book chapters on biologics and vaccines and peer-reviewed journal articles. Lisa is also a member of the BioSafe Specialty Biologics Expert working group for vaccines and the HESI ILSI Immunotoxicology Technical Committee. Lisa received a B.A in Biology from The State University of New York at Oswego and an M.S. and a Ph.D. in Immunology from the Albany Medical College. Following her graduate work she did a postdoctoral fellowship with a focus on Immunotoxicology in the Curriculum in Toxicology at the University of North Carolina at Chapel Hill which was part of a Cooperative Research and Development Agreement with Dow Chemical and DuPont.